ALS-8112 (Cat.No:I001710), also known as tirabrutinib, is a reversible, orally available Bruton’s tyrosine kinase (BTK) inhibitor. It is used for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). ALS-8112 blocks BTK activity, which is involved in the activation of B-cells and their proliferation, ultimately leading to apoptosis of cancerous cells.
Catalog Number | I001710 |
CAS Number | 1445379-92-9 |
Molecular Formula | C10H13ClFN3O4 |
Purity | ≥95% |
Target | RSV |
Solubility | DMSO: > 47 mg/mL |
Storage | Store at -20°C |
IC50 | 0.15 μM (EC50) [2] |
IUPAC Name | 4-amino-1-[(2R,3R,4R,5R)-5-(chloromethyl)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one |
InChI | InChI=1S/C10H13ClFN3O4/c11-3-10(4-16)7(17)6(12)8(19-10)15-2-1-5(13)14-9(15)18/h1-2,6-8,16-17H,3-4H2,(H2,13,14,18)/t6-,7+,8-,10-/m1/s1 |
InChIKey | AWSRKKBIPSQHOJ-IBCQBUCCSA-N |
SMILES | OC[C@]1(CCl)[C@H]([C@@H](F)[C@H](N2C(N=C(C=C2)N)=O)O1)O |
Reference | <p style=/line-height:25px/> |